Mariners knew that there were dangers in uncharted waters and those that wandered there may not come back. It is safe to work with aptamers in controlled buffers and many papers have been published detailing how well they work close to the shore where maps… Lire la suite »Signal vs Noise II – Aptamer Signal Amplification
Signal versus noise is not only the core basis of the development of diagnostic devices but the core basis of all scientific questions. This may be the core question of our individual existence as a brief scream against the silence of the universe, but that… Lire la suite »Signal vs Noise I – The Core of the Signal-to-Noise Ratio
At NeoVentures we are the global leaders in the identification of aptamers against viruses. We have developed aptamers against HIV, HCV, HSV, rhinovirus, and SARS-CoV-2 for a broad range of applications from neutralization of infection to diagnosis. Why aptamers for these applications? For neutralization of… Lire la suite »Aptamers for Viruses – Prevention and Diagnosis
Why consider aptamers for therapeutic applications? There has only been one aptamer based therapeutic ever approved, Macugen (https://en.wikipedia.org/wiki/Pegaptanib) and the commercial sales for this treatment were not blockbuster… The biggest issue facing any therapeutic development effort is definitely the risk of failure, especially the risk… Lire la suite »Why Consider Aptamers for Therapeutic Applications?
We have succeeded in developing high affinity and high specificity aptamers for both the spike protein (S1) and the nucleoprotein from SARS-CoV-2 (COVID-19). These aptamers have been characterized and are available for purchase. We are working with several partners globally to apply these aptamers in… Lire la suite »NeoVentures Develops Aptamers for COVID-19
NeoVentures has successfully developed aptamers for both the spike protein and the nucleoprotein of SARS-CoV-2 (COVID-19). Spike protein aptamers were developed against a recombinant S1 protein from the Wuhan strain expressed in HEK293 cells in order to maintain appropriate glycosylation, counter selection was performed against… Lire la suite »High-Specificity Aptamers for SARS-CoV-2
Why are there not more aptamer based therapeutics? This blog by Drew Smith in 2019 nails a lot of the reasons, and in particular the issues related to the rapid clearance of aptamers from the body. https://drewsmithblog.com/2019/05/aptamers-still-looking-for-euphoria-in-the-wrong-places/. He effectively points out that the aptamer that… Lire la suite »Aptamers in Therapeutics ? (Why not)
In a previous blog I stressed the need to further improve aptamer performance after SELEX identification in order to develop aptamers that are effective enough to be commercialized. I promised that I would describe how we do this at NeoVentures in more detail in a… Lire la suite »Optimized Aptamers II
For aptamers to be able to compete with antibodies in healthcare applications they need to perform as well as antibodies. At NeoVentures we have considered how antibodies evolve in response to an antigen and we have applied a similar approach to our optimized aptamers. The… Lire la suite »Optimized Aptamers
French 
English 
Spanish